Abstract
Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.
| Original language | English |
|---|---|
| Pages (from-to) | 90-94 |
| Number of pages | 5 |
| Journal | Liver International |
| Volume | 31 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - Jan 2011 |
Fingerprint
Keywords
- HBeAg-negative
- Hepatitis B
- PEG-IFNα sustained response
ASJC Scopus subject areas
- Hepatology
Cite this
Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. / Lampertico, Pietro; Viganò, Mauro; Colombo, Massimo.
In: Liver International, Vol. 31, No. SUPPL. 1, 01.2011, p. 90-94.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon
AU - Lampertico, Pietro
AU - Viganò, Mauro
AU - Colombo, Massimo
PY - 2011/1
Y1 - 2011/1
N2 - Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.
AB - Serum HBeAg-negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long-term nucleot(s)ide therapy or 1-year administration of pegylated interferon (PEG-IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG-IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long-term efficacy of PEG-IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG-IFN as early as possible in primary non-responders and extended therapy (up to 96 weeks) in responders.
KW - HBeAg-negative
KW - Hepatitis B
KW - PEG-IFNα sustained response
UR - http://www.scopus.com/inward/record.url?scp=78650821453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650821453&partnerID=8YFLogxK
U2 - 10.1111/j.1478-3231.2010.02386.x
DO - 10.1111/j.1478-3231.2010.02386.x
M3 - Article
C2 - 21205144
AN - SCOPUS:78650821453
VL - 31
SP - 90
EP - 94
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - SUPPL. 1
ER -